Abstract:Objective To explore the screening efficiency about the first trimester screening of pregnancy-associated plasma protein A (PAPP-A)combined with the second trimester screening of alpha fetoprotein (AFP),free β-human cho-rionic gonadotropin (free β-HCG),uncojugated estriol (uE3)strategies for Down's Syndrome (DS)and Edwards' syn-drome (ES). Methods The clinical data from 7055 cases of pregnant women with pregnancy outcome,who underwent prenatal screening test,were retrospectively analyzed. The serum PAPP-A,free β-hCG in the first trimester,and AFP, free β-HCG,and uE3 in the second trimester were detected in all pregnant women. We designed three screening tests as three groups:projects A,B,and C. The risk evaluation of project A was serum free β-hCG and PAPP-A levels in the first trimester screening. Project B included free β-hCG,AFP,and uE3 levels in the second trimester. As for project C - so called the integrated serum test,included the serum PAPP-A levels in the first trimester,and AFP,β-hCG,and uE3 in the second trimester. The risks of DS and ES were evaluated by LifeCycle 4. 0 software based on the age,weight and gesta-tional week of gravidas. The cut-off value (high risk)and the intermediate risk value were > 1 / 270 and 1 / 1000 - 1 / 270 in DS,> 1 / 350 and 1 / 1000-1 / 350 in ES,respectively. We compared the high risk rate,intermediate risk rate in both DS and ES as well as the total positive rates among the three screening tests mentioned above. The women who terminated preg-nancy were identified by prenatal diagnosis via amniocentesis. Furthermore,those who did not terminate pregnancy were confirmed by the pregnancy outcomes,and were followed up based on karyotype of newborns. We evaluated screening effi-ciency of DS and ES such as the detection rate (DR)and false positive rate (FPR)among the three screening strategies. Results The high risk and the intermediate risk in DS as well as the screening positive rate of the project C were signifi-cant lower than those of projects A and B,respectively (P < 0. 05)(neural tube defect were excluded). A total of 9 fetus with true DS were diagnosed via amniocentesis and follow-up pregnancy outcomes. In the project A,the number of high risk was 7,DR and FPR for trisomy 21 was 77. 8% (7 / 9)and 3. 95% (279 / 7055),respectively. In the project B,the num-ber of high risk was 6,DR and FPR for trisomy 21 was 66. 7% (6 / 9)and 4. 24% (299 / 7055),respectively. In the project C,DR and FPR for trisomy 21 was 88. 9% (8 / 9)and 1. 80% (127 / 7055),respectively. The DR and FPR for DS in the project C were both superior to those in the projects A and B (DR:P > 0. 05,FPR:P < 0. 05). We diagnosed two fetus with true ES through amniocentesis and follow-up pregnancy outcomes. Only one case was successfully detected by all three screening projects. The other case was detected as high risk in the combined screening test. The detection rate for ES in the project C was higher than those in both projects A and B. Conclusion The screening efficiency about the first trimester screening of PAPP-A combined with the second trimester screening of AFP,free β-HCG,and uE3 for DS and ES is superior to both the first trimester double test (PAPP-A and free β-HCG)and the second trimester triple test including AFP,free β-HCG,and uE3.

Establishment of median value for screening serum-markers in first-trimester prenatal screening and investigation of its clinical significance in Wuxi

Standardization and application of median equation of AFP,free β-HCG and uE3 in the second trimester of pregnant women in Wuxi

Predictive Significance of Risk Value in Prenatal Screening for Fetal Trisomy 18

[Establishment and application of median serum markers for second trimester screening in Qingdao region]

Reference Intervals For Biochemical, Haemostatic And Haematological Parameters In Healthy Chinese Women During Early And Late Pregnancy

[Establishment of medians for maternal serum markers in Down's syndrome screening during the second trimester of pregnancy in north-central region of Jiangxi Province]

The analysis of second-trimester triple screening for Down syndrome in Chinese normal singleton pregnancies

Evaluating the Applicability of MoM in Second Trimester Maternal Serum to Screening for Down's Syndrome in Jiangsu Province

MoM Correction Model of Maternal Serum Markers in Screening the Patients with Down Syndrome at Second Trimester

Second‐trimester Maternal Serum Free‐β‐human Chorionic Gonadotropin and Α‐fetoprotein Levels in Normal Twin and Singleton Pregnancies: a Report of Local Chinese Population

Second-trimester maternal serum free-beta-human chorionic gonadotropin and alpha-fetoprotein levels in normal twin and singleton pregnancies: a report of local Chinese population

Study on the use of second trimester maternal serum screening for Down's syndrome.

The Status of Quality Control Investigation and Analysis for Maternal Serum Marker of Prenatal Screening Laboratories in China

Screening efficiency about the first trimester screening of PAPP-A combined with the second trimester screening of AFP,free β-HCG,and uE3 strategies for Down's Syndrome and Edwards'syndrome

Efficiency of Non-invasive Prenatal Screening in Pregnant Women at Advanced Maternal Age

[Evaluation of Down's syndrome screening methods using maternal serum biochemistry in the second trimester pregnancy]

Comparison of Second-Trimester Maternal Serum Free-Beta-human Chorionic Gonadotropin and Alpha-Fetoprotein Between Normal Singleton and Twin Pregnancies: a Population-Based Study.

Proficiency testing of maternal serum prenatal screening in second trimester in China, 2015

An assessment of analytical performance using the six sigma scale in second-trimester maternal prenatal screening practices in China

Evaluation of Maternal Serum sHLA-G Levels for Trisomy 18 Fetuses Screening at Second Trimester

Improved contingent screening strategy increased trisomy 21 detection rate in the second trimester